Deutsche Bank Starts Teva Pharma (TEVA) at Buy
- Fed Stress Test Shows all 31 Banks Exceed Minimum Requirements (JPM) (GS) (MS) (WFC) (BAC)
- Market Wrap: Banks Ace Stress Test; ECB Favorable on Outlook; Etsy Looks to go Public
- AbbVie (ABBV) to Acquire Pharmacyclics (PCYC) for $21 Billion
- Wall Street Takes Sides Ahead of Apple Watch Event (AAPL)
- The Fresh Market (TFM) Tops Q4 EPS by 4c; Will Shutter Some California Operations
Deutsche Bank initiated coverage on Teva Pharma (NYSE: TEVA) with a Buy rating and a price target of $63.00.
Analyst Gregg Gilbert said, "While the potential cliff for Copaxone looms and the generics business has not been without challenges, we like the combination of valuation, attractive dividend yield (similar to Big Pharma), and the potential for greater focus on strategic initiatives that increase shareholder value under new CEO Erez Vigodman. We see the recent hire of industry veteran Siggi Olafsson to run global generics and the simplification of the management structure as positive steps, and we sense that investors are skeptical about cost savings initiatives, the entire branded product pipeline, and Teva’s ability/desire to do deals."
Shares of Teva Pharma closed at $54.95 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Starts Time Warner (TWX) at Buy
- Deutsche Bank Starts CBS (CBS) at Hold
- Deutsche Bank Starts Viacom (VIAB) at Buy
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View, New Coverage
Related EntitiesDeutsche Bank, Dividend
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!